• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

by Elena Iemma | Jun 10, 2022 | News

PROVIDENCE, RI, June 10, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National...
EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

by Elena Iemma | May 25, 2022 | News

PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration...
EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

by Elena Iemma | Nov 30, 2021 | News

PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc....

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline